EXPERIENCE OF TREATMENT WITH LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (RVD) IN THE FIRST LINE IN PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA IN THE HOSPITALS OF ARAGON AND THE PROVINCE OF SORIA

被引：0

作者：

Yus Cebrian, F. ^{[1
]}

Paul Vidaller, P. J. ^{[1
]}

Romero Quezada, L. L. ^{[1
]}

Perella Arnal, M., I ^{[1
]}

Campuzano Saavedra, V ^{[2
]}

Sancho Val, L., I ^{[3
]}

Gonzalez Gomez, N. ^{[4
]}

Marco Amigot, J. J. ^{[5
]}

Murillo Flores, I. M. ^{[5
]}

Carrasco Baraja, V ^{[6
]}

Godoy Molias, A. C. ^{[7
]}

Paricio Moreno, M. ^{[3
]}

Malo Yague, M. ^{[8
]}

Delgado Beltran, M. P. ^{[7
]}

Aguilar Franco, C. ^{[2
]}

Palomera Bernal, L. R. ^{[9
]}

机构：

[1] Hosp Barbastro, Huesca, Huesca, Spain

[2] Hosp Santa Barbara, Puertollano, Spain

[3] Hosp Alcaniz, Alcaniz, Teruel, Spain

[4] Hosp Obispo Polanco, Teruel, Spain

[5] Hosp San Jorge, Huesca, Spain

[6] Hosp Royo Villanova, Zaragoza, Spain

[7] Hosp Miguel Servet, Zaragoza, Spain

[8] Hosp Ernest Lluch, Zaragoza, Spain

[9] Hosp Clin Lozano Blesa, Zaragoza, Spain

来源：

HAEMATOLOGICA | 2017年 / 102卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PC-013

引用

页码：97 / 97

页数：1

共 50 条

[41] Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction.
Harvey, R. Donald
Kaufman, Jonathan L.
Heffner, Leonard T.
Hofmeister, Craig C.
Dhodapkar, Mahdav V.
Lonial, Sagar
Nooka, Ajay K.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[42] BORTEZOMIB IN THE FIRST-LINE TREATMENT OF MULTIPLE MYELOMA: THE EXPERIENCE OF A CENTER
Mendes, M. J.
Ferreira, G.
Saturnino, H.
Duarte, M.
Almeida, J. C.
Arajo, L. F.
Ribeiro, M. L.
HAEMATOLOGICA, 2015, 100 : 735 - 735
[43] Early mortality and treatment discontinuation in multiple myeloma patients treated in front-line with bortezomib, lenalidomide and dexamethasone (VRD)
Oriol, Albert
Canelo-Vilaseca, Marta
Sanchez, Carla
Abril, Laura
Escoda, Lourdes
Ibarra, Gladys
Abella, Eugenia
Motllo, Cristina
Gonzalez-Montes, Yolanda
Granada, Isabel
Cabezudo, Elena
Senin, Alicia
Ben, Randa
Jurado, Rebeca
de Jaureguizar, Alejandro
Ribera, Josep-Maria
Sarra, Josep
Sancho, Juan-Manuel
Sureda, Anna
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S146 - S147
[44] Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment
Saeed, Nabiha
Khan, Zurrya
Jehanzeb, Hamzah
Shaikh, Taha
Shaikh, Usman
Adil, Salman N.
Madni, Varisha
Fatima, Hania
Abiha, Umm E.
Ali, Natasha
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
[45] BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE VERSUS BORTEZOMIB-CYCLOPHOSPHAMIDE- DEXAMETHASONE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
Al-Hashmi, H.
LEUKEMIA RESEARCH, 2017, 61 : S55 - S55
[46] Bortezomib-lenalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation: A single center experience
Kaloyannidis, P.
Abduljalil, O.
Abdulbaqi, M.
Jatham, A.
Estanislao, A.
Raslan, H.
Moinuddin, A.
Apostolidis, J.
Al Sagheir, A.
Al Hashmi, H.
Al Anazi, K.
BONE MARROW TRANSPLANTATION, 2017, 52 : S462 - S462
[47] Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Korde, Neha
Roschewski, Mark
Zingone, Adriana
Kwok, Mary
Manasanch, Elisabet E.
Bhutani, Manisha
Tageja, Nishant
Kazandjian, Dickran
Mailankody, Sham
Wu, Peter
Morrison, Candis
Costello, Rene
Zhang, Yong
Burton, Debra
Mulquin, Marcia
Zuchlinski, Diamond
Lamping, Liz
Carpenter, Ashley
Wall, Yvonne
Carter, George
Cunningham, Schuyler C.
Gounden, Verena
Sissung, Tristan M.
Peer, Cody
Maric, Irina
Calvo, Katherine R.
Braylan, Raul
Yuan, Constance
Stetler-Stevenson, Maryalice
Arthur, Diane C.
Kong, Katherine A.
Weng, Li
Faham, Malek
Lindenberg, Liza
Kurdziel, Karen
Choyke, Peter
Steinberg, Seth M.
Figg, William
Landgren, Ola
JAMA ONCOLOGY, 2015, 1 (06) : 746 - 754
[48] Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma
Tan, Carlyn
Maclachlan, Kylee H.
Nemirovsky, David
Derkach, Andriy
Hultcrantz, Malin
Hassoun, Hani
Mailankody, Sham
Shah, Urvi A.
Rajeeve, Sridevi
Patel, Dhwani
Shekarkhand, Tala
Rueda, Colin
Lahoud, Oscar Boutros
Shah, Gunjan L.
Scordo, Michael
Chung, David
Landau, Heather
Giralt, Sergio A.
Lesokhin, Alexander
Usmani, Saad Z.
BLOOD, 2023, 142
[49] Lenalidomide, Bortezomib, and Dexamethasone (RVD) In Combination with Vorinostat as Front-Line Therapy for Patients with Multiple Myeloma (MM): Initial Results of a Phase 1 Study.
Kaufman, Jonathan L.
Shah, Jatin J.
Laubach, Jacob P.
Heffner, Leonard
Francis, Dixil
Harvey, R. Donald
Lewis, Colleen
Tighiouart, Mourad
Richardson, Paul
Orlowski, Robert Z.
Lonial, Sagar
BLOOD, 2010, 116 (21) : 1251 - 1251
[50] Daratumumab (DARA) plus lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFIN
Nooka, Ajay
Kaufman, Jonathan
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne
Reeves, Brandi
Wildes, Tanya
Holstein, Sarah
Anderson, Larry
Badros, Ashraf
Shune, Leyla
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas
Usmani, Saad
Richardson, Paul
Voorhees, Peter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S155 - S156

← 1 2 3 4 5 →